论文部分内容阅读
目的探讨尤瑞克林联合依达拉奉治疗缺血性脑卒中的临床疗效及安全性。方法将40例急性缺血脑卒中患者随机分为联合治疗组和对照组,联合治疗组:尤瑞克林针联合依达拉奉针静滴治疗;对照组:单用依达拉奉针静滴;疗程均为14d;治疗前、治疗后14d分别进行美国国立卫生研究院卒中量表(theNational Institutes of Health Stroke Scale,NIHSS)评分,同时于治疗前、后第14及90d行日常生活活动能力量表(Activities of Daily Living Scale,ADL)评分。结果联合治疗组和对照组治疗前、治疗后14d NIHSS评分组内比较有明显差异(P<0.01),有效率分别为80%及75%,组间比较无差异(P>0.05)。联合治疗组和对照组治疗后第14d的ADL评分组间比较无差异(P>0.05),治疗后第90d的ADL评分组间比较有差异(P<0.01)。结论在缺血性脑卒中的治疗中尤瑞克林联合依达拉奉能有效、安全发挥疗效;其急性期疗效与单用依达拉奉比较无明显差异,但远期疗效及改善患者日常生活活动能力方面明显优于单用依达拉奉。
Objective To investigate the clinical efficacy and safety of uracil combined with edaravone in the treatment of ischemic stroke. Methods Forty patients with acute ischemic stroke were randomly divided into the treatment group and the control group. The combination therapy group was treated with urelin needle and edaravone needle. The control group was treated with edaravone alone The courses of treatment were 14 days before treatment and 14 days after treatment. The NIHSS scores of NIH were also calculated before and 14 days after treatment. The daily living activities Activities of Daily Living Scale (ADL) score. Results There were significant differences in the NIHSS scores between the two groups (P <0.01) before and after treatment. The effective rates were 80% and 75%, respectively. There was no significant difference between the two groups (P> 0.05). There was no significant difference (P> 0.05) between the ADL score of the 14th day after treatment in the combination therapy group and the control group, and there was a significant difference (P <0.01) between the ADL score of the 90th day after treatment. Conclusion In the treatment of ischemic stroke, uracil combined edaravone can effectively and safely exert its curative effect. There is no significant difference between the two groups in the acute phase and edaravone alone. However, the long-term curative effect and improvement of daily Life activity was significantly better than edaravone alone.